205 related articles for article (PubMed ID: 18603821)
21. Comparative efficacy and safety of low-dose pitavastatin versus atorvastatin in patients with hypercholesterolemia.
Sansanayudh N; Wongwiwatthananukit S; Putwai P; Dhumma-Upakorn R
Ann Pharmacother; 2010 Mar; 44(3):415-23. PubMed ID: 20179259
[TBL] [Abstract][Full Text] [Related]
22. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
Jones PH; Hunninghake DB; Ferdinand KC; Stein EA; Gold A; Caplan RJ; Blasetto JW;
Clin Ther; 2004 Sep; 26(9):1388-99. PubMed ID: 15531001
[TBL] [Abstract][Full Text] [Related]
23. Effects of atorvastatin on Lp(a) and lipoprotein profiles in hemodialysis patients.
Joy MS; Dornbrook-Lavender KA; Chin H; Hogan SL; Denu-Ciocca C
Ann Pharmacother; 2008 Jan; 42(1):9-15. PubMed ID: 18000162
[TBL] [Abstract][Full Text] [Related]
24. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin.
Stein E; Stender S; Mata P; Sager P; Ponsonnet D; Melani L; Lipka L; Suresh R; Maccubbin D; Veltri E;
Am Heart J; 2004 Sep; 148(3):447-55. PubMed ID: 15389231
[TBL] [Abstract][Full Text] [Related]
25. Effect of Ezetimibe on LDL-C Lowering and Atherogenic Lipoprotein Profiles in Type 2 Diabetic Patients Poorly Controlled by Statins.
Sakamoto K; Kawamura M; Kohro T; Omura M; Watanabe T; Ashidate K; Horiuchi T; Hara H; Sekine N; Chin R; Tsujino M; Hiyoshi T; Tagami M; Tanaka A; Mori Y; Inazawa T; Hirano T; Yamazaki T; Shiba T;
PLoS One; 2015; 10(9):e0138332. PubMed ID: 26398887
[TBL] [Abstract][Full Text] [Related]
26. The anti-atherosclerotic effects of lipid lowering with atorvastatin in patients with hypercholesterolemia.
Ozaki K; Kubo T; Imaki R; Shinagawa H; Fukaya H; Ohtaki K; Ozaki S; Izumi T; Aizawa Y
J Atheroscler Thromb; 2006 Aug; 13(4):216-9. PubMed ID: 16908955
[TBL] [Abstract][Full Text] [Related]
27. Time course differences for statin-induced pleiotropic effects in hypercholesterolemic patients.
Sakabe K; Fukuda N; Wakayama K; Nada T; Shinohara H; Tamura Y
Int J Cardiol; 2004 Mar; 94(1):111-7. PubMed ID: 14996484
[TBL] [Abstract][Full Text] [Related]
28. The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL-C Value--an Evaluation of Rosuvastatin therapY compared with atorvastatin.
Fonseca FA; Ruiz A; Cardona-Muñoz EG; Silva JM; Fuenmayor N; Marotti M;
Curr Med Res Opin; 2005 Aug; 21(8):1307-15. PubMed ID: 16083541
[TBL] [Abstract][Full Text] [Related]
29. Effects of pitavastatin and atorvastatin on lipoprotein oxidation biomarkers in patients with dyslipidemia.
Yoshida H; Shoda T; Yanai H; Ikewaki K; Kurata H; Ito K; Furutani N; Tada N; Witztum JL; Tsimikas S
Atherosclerosis; 2013 Jan; 226(1):161-4. PubMed ID: 23174369
[TBL] [Abstract][Full Text] [Related]
30. Comparison of pitavastatin with atorvastatin in increasing HDL-cholesterol and adiponectin in patients with dyslipidemia and coronary artery disease: the COMPACT-CAD study.
Kurogi K; Sugiyama S; Sakamoto K; Tayama S; Nakamura S; Biwa T; Matsui K; Ogawa H;
J Cardiol; 2013 Aug; 62(2):87-94. PubMed ID: 23672789
[TBL] [Abstract][Full Text] [Related]
31. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial.
Robinson JG; Nedergaard BS; Rogers WJ; Fialkow J; Neutel JM; Ramstad D; Somaratne R; Legg JC; Nelson P; Scott R; Wasserman SM; Weiss R;
JAMA; 2014 May; 311(18):1870-82. PubMed ID: 24825642
[TBL] [Abstract][Full Text] [Related]
32. Effects of increasing doses of atorvastatin on the atherogenic lipid subclasses commonly associated with hypertriglyceridemia.
Karalis DG; Ishisaka DY; Luo D; Ntanios F; Wun CC
Am J Cardiol; 2007 Aug; 100(3):445-9. PubMed ID: 17659926
[TBL] [Abstract][Full Text] [Related]
33. Paradoxical negative HDL cholesterol response to atorvastatin and simvastatin treatment in Chinese type 2 diabetic patients.
Chang YH; Lin KC; Chang DM; Hsieh CH; Lee YJ
Rev Diabet Stud; 2013; 10(2-3):213-22. PubMed ID: 24380094
[TBL] [Abstract][Full Text] [Related]
34. A multicentre, open study to assess the effect of individualizing starting doses of atorvastatin according to baseline LDL-C levels on achieving cholesterol targets: the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST-2) study.
Farsang C; Athyros V; Gaw A;
Curr Med Res Opin; 2007 Aug; 23(8):1945-56. PubMed ID: 17626713
[TBL] [Abstract][Full Text] [Related]
35. Gender differences in short-term effects of atorvastatin on lipid profile, fibrinolytic parameters, and endothelial function.
Sakabe K; Fukuda N; Fukuda Y; Wakayama K; Nada T; Morishita S; Shinohara H; Tamura Y
Nutr Metab Cardiovasc Dis; 2008 Mar; 18(3):182-8. PubMed ID: 17399968
[TBL] [Abstract][Full Text] [Related]
36. Improvement of endothelial dysfunction is mediated through reduction of remnant lipoprotein after statin therapy in patients with coronary artery disease.
Nakamura T; Uematsu M; Yoshizaki T; Kobayashi T; Watanabe Y; Kugiyama K
J Cardiol; 2020 Mar; 75(3):270-274. PubMed ID: 31500961
[TBL] [Abstract][Full Text] [Related]
37. Distinct effects of pitavastatin and atorvastatin on lipoprotein subclasses in patients with Type 2 diabetes mellitus.
Shimabukuro M; Higa M; Tanaka H; Shimabukuro T; Yamakawa K; Masuzaki H
Diabet Med; 2011 Jul; 28(7):856-64. PubMed ID: 21244474
[TBL] [Abstract][Full Text] [Related]
38. Lipid and apoprotein changes during atorvastatin up-titration in hemodialysis patients with hypercholesterolemia: a placebo-controlled study.
Lins RL; Matthys KE; Billiouw JM; Dratwa M; Dupont P; Lameire NH; Peeters PC; Stolear JC; Tielemans C; Maes B; Verpooten GA; Ducobu J; Carpentier YA
Clin Nephrol; 2004 Oct; 62(4):287-94. PubMed ID: 15524059
[TBL] [Abstract][Full Text] [Related]
39. Effects of atorvastatin and atorvastatin withdrawal on soluble CD40L and adipocytokines in patients with hypercholesterolaemia.
Chu CS; Lee KT; Lee MY; Su HM; Voon WC; Sheu SH; Lai WT
Acta Cardiol; 2006 Jun; 61(3):263-9. PubMed ID: 16869445
[TBL] [Abstract][Full Text] [Related]
40. Non-high-density lipoprotein cholesterol: a target of lipid-lowering in dialysis patients.
Wanner C; Krane V
Am J Kidney Dis; 2003 Mar; 41(3 Suppl 1):S72-5. PubMed ID: 12612957
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
